ACUT (Accustem Sciences) Tariff Resilience Score: 8/10 (As of Jul. 11, 2026)


ACUT Accustem Sciences Inc ACUT
27 GF Score
Price $0.19
! 1 Warning Sign
View Full Analysis

What is Accustem Sciences Tariff Resilience Score?

Accustem Sciences ACUT +21.61% 27 Tariff Resilience Score is 8 as of Jul. 11, 2026. GuruFocus rates ACUT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,369 Biotechnology companies, Accustem Sciences ranks better than 98.69% on this metric.

Accustem Sciences has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Accustem Sciences has Accustem Sciences, focused on healthcare, has minimal exposure to tariffs due to its emphasis on innovation and domestic operations. The industry benefits from exemptions, and the company has strong pricing power. Global supply chain dependencies are limited.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Accustem Sciences might have Highly Resilient.

Accustem Sciences  (OTCPK:ACUT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Accustem Sciences Tariff Resilience Score Related Terms

ACUT vs DCOY, BIXT, SPRC: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Accustem Sciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Tariff Resilience Score falls into.


ACUT
27GF Score
Accustem Sciences Inc ACUT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Accustem Sciences (ACUT) has a Tariff Resilience Score of 8 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Accustem Sciences ranks #18 out of 1369 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Accustem Sciences' Tariff Resilience Score too high?
Accustem Sciences' current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Accustem Sciences' value of 8 is 100% above this industry median. Based on the distribution chart, Accustem Sciences ranks #18 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Accustem Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Accustem Sciences' Tariff Resilience Score compare to DCOY and BIXT?
According to the Biotechnology industry distribution chart, Accustem Sciences ranks #18 out of 1369 companies for Tariff Resilience Score. This places Accustem Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Accustem Sciences' value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accustem Sciences's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accustem Sciences's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accustem Sciences stock overvalued right now?
Accustem Sciences (ACUT) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Accustem Sciences' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Accustem Sciences (ACUT), the current Tariff Resilience Score is 8 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accustem Sciences Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10001
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
27GF Score

Get the complete analysis for ACUT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price